- |||||||||| Review, Journal: New Pharmacologic Approaches to the Treatment of Bipolar Depression. (Pubmed Central) - May 25, 2023
New atypical anti-psychotics lumateperone and cariprazine have demonstrated efficacy in large-scale, placebo-controlled, double-blind randomized controlled trials (RCT) in treatment of BD depression...While there are potentially efficacious, mechanistically novel agents on the horizon, they require further study and validation. Further investigation on how these agents may impact specific subgroups of patients will also advance the field.
- |||||||||| ketamine/D-cycloserine/lurasidone (NRX-100/NRX-101) / NRx Pharma, ketamine intravenous (NRX100) / NRx Pharma, Cyclurad (cycloserine/lurasidone) / NRx Pharma, Alvogen
Trial completion, Trial primary completion date: STABIL-B: Sequential Therapy for the Treatment of Severe Bipolar Depression. (clinicaltrials.gov) - Nov 30, 2018
P2, N=20, Completed,
Further investigation on how these agents may impact specific subgroups of patients will also advance the field. Active, not recruiting --> Completed | Trial primary completion date: Dec 2018 --> Aug 2018
- |||||||||| ketamine/D-cycloserine/lurasidone (NRX-100/NRX-101) / NRx Pharma, ketamine intravenous (NRX100) / NRx Pharma, Cyclurad (cycloserine/lurasidone) / NRx Pharma, Alvogen
Enrollment closed, Enrollment change: STABIL-B: Sequential Therapy for the Treatment of Severe Bipolar Depression. (clinicaltrials.gov) - Aug 27, 2018
P2, N=20, Active, not recruiting,
Active, not recruiting --> Completed | Trial primary completion date: Dec 2018 --> Aug 2018 Recruiting --> Active, not recruiting | N=120 --> 20
- |||||||||| ketamine/D-cycloserine/lurasidone (NRX-100/NRX-101) / NRx Pharma, ketamine intravenous (NRX100) / NRx Pharma, Cyclurad (cycloserine/lurasidone) / NRx Pharma, Alvogen
Enrollment open, Phase classification: STABIL-B: Sequential Therapy for the Treatment of Severe Bipolar Depression. (clinicaltrials.gov) - Mar 8, 2018
P2, N=120, Recruiting,
Recruiting --> Active, not recruiting | N=120 --> 20 Not yet recruiting --> Recruiting | Phase classification: P2/3 --> P2
- |||||||||| ketamine/D-cycloserine/lurasidone (NRX-100/NRX-101) / NRx Pharma, ketamine intravenous (NRX100) / NRx Pharma, Cyclurad (cycloserine/lurasidone) / NRx Pharma, Alvogen
Trial initiation date: STABIL-B: Sequential Therapy for the Treatment of Severe Bipolar Depression. (clinicaltrials.gov) - Jan 9, 2018
P2/3, N=120, Not yet recruiting,
Not yet recruiting --> Recruiting | Phase classification: P2/3 --> P2 Initiation date: Jun 2017 --> Jan 2018
- |||||||||| ketamine/D-cycloserine/lurasidone (NRX-100/NRX-101) / NRx Pharma, ketamine intravenous (NRX100) / NRx Pharma, Cyclurad (cycloserine/lurasidone) / NRx Pharma, Alvogen
Trial initiation date: STABIL-B: Sequential Therapy for the Treatment of Severe Bipolar Depression. (clinicaltrials.gov) - Mar 27, 2017
P2/3, N=120, Not yet recruiting,
Initiation date: Jun 2017 --> Jan 2018 Initiation date: Jan 2017 --> Jun 2017
|
